Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults

Abstract The vaccine efficacy of standard-dose seasonal inactivated influenza vaccines (S-IIV) can be improved by the use of vaccines with higher antigen content or adjuvants. We conducted a randomized controlled trial in older adults to compare cellular and antibody responses of S-IIV versus enhanc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Athena P. Y. Li, Carolyn A. Cohen, Nancy H. L. Leung, Vicky J. Fang, Shivaprakash Gangappa, Suryaprakash Sambhara, Min Z. Levine, A. Danielle Iuliano, Ranawaka A. P. M. Perera, Dennis K. M. Ip, J. S. Malik Peiris, Mark G. Thompson, Benjamin J. Cowling, Sophie A. Valkenburg
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ff75dec103104784802c673035cff753
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults

Ejemplares similares